Education
About Us
Working with TipRanks
Follow Us
Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
IMDX Stock Chart & Stats
$6.52
--
Market closed
$6.52
--
Day’s Range― - ―
52-Week Range$1.95 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$186.89M
Enterprise Value$171.33M
Total Cash (Recent Filing)$18.69M
Total Debt (Recent Filing)$3.13M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Apr 01, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding28,664,436
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.53
Price to Sales (P/S)16.54
P/FCF Ratio-1.47
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue38.92
Enterprise Value/Gross Profit71.12
Enterprise Value/Ebitda-2.93
Forecast
1Y Price Target
$8.50Price Target Upside30.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Adoption And Evidence GenerationGraftAssureIQ's use at clinical sites across North America and Europe, paired with a planned 5,000-patient registry using GraftAssureCore, could build strong clinical evidence and create a recurring revenue opportunity.
Commercial PartnershipIMDX's partnership with BioRad to co-market GraftAssure in the US and Germany, with BioRad leading international commercialization elsewhere, supports wider distribution and faster global rollout.
Regulatory ProgressAnalyst noted the company is nearing completion of its FDA submission for GraftAssureDx, indicating the test is ready for formal regulatory review and could accelerate market entry upon approval.
Bears Say
Cash Burn And Financing RiskCash burn may exceed the company's target of roughly $6 million per quarter, increasing the likelihood of additional financing needs that could dilute shareholders.
Margin PressureReported gross margin fell to 53%, down from 67% in the prior quarter, signaling near-term margin pressure as the business scales its operations.
Regulatory Timing RiskA full FDA submission that lags earlier targets introduces regulatory timing risk that could delay key commercialization milestones.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $1.95 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $186.89M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Apr 01, 2026 which is in 59 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Nov 10, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.21 by $0.01.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 28,664,436 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.21. Following the earnings report the stock price went up 10.588%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (30.37% Upside)
$8.50 (30.37% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
-9999.00%
Trailing 12-Months
Asset Growth
-32.39%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
IMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a generally positive outlook with significant advancements in product development and financial stability. However, the uncertainty due to the government shutdown and slower-than-expected clinical trial enrollment presents challenges.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$8.50
▲(30.37% Upside)